difficulty understanding speech in the presence of background noise (cocktail party effect)
sounds or speech sounding dull, muffled or attenuated
need for increased volume on television, radio, music and other audio sourcesHearing loss is sensory, but may have accompanying symptoms:

pain or pressure in the ears
a blocked feelingThere may also be accompanying secondary symptoms:

hyperacusis, heightened sensitivity with accompanying auditory pain to certain intensities and frequencies of sound, sometimes defined as "auditory recruitment"
tinnitus, ringing, buzzing, hissing or other sounds in the ear when no external sound is present
vertigo and disequilibrium
tympanophonia, also known as autophonia, abnormal hearing of ones own voice and respiratory sounds, usually as a result of a patulous (a constantly open) eustachian tube or dehiscent superior semicircular canals
disturbances of facial movement (indicating a possible tumour or stroke) or in persons with Bells palsy

Complications
Hearing loss is associated with Alzheimers disease and dementia. The risk increases with the hearing loss degree. There are several hypotheses including cognitive resources being redistributed to hearing and social isolation from hearing loss having a negative effect. According to preliminary data, hearing aid usage can slow down the decline in cognitive functions.Hearing loss is responsible for causing thalamocortical dysrthymia in the brain which is a cause for several neurological disorders including tinnitus and visual snow syndrome. Cognitive decline
Hearing loss is an increasing concern especially in aging populations. The prevalence of hearing loss increases about two-fold for each decade increase in age after age 40.
Gene therapy approaches for treating FVII deficiency are very promising ()

Medical uses
Recombinant factor VIIa, marketed under the trade names AryoSeven and NovoSeven, is used for people with hemophilia (with Factor VIII or IX deficiency) who have developed antibodies against replacement coagulation factor. It has also been used in the setting of uncontrollable hemorrhage, but its role in this setting is controversial with insufficient evidence to support its use outside of clinical trials. The first report of its use in hemorrhage was in an Israeli soldier with uncontrollable bleeding in 1999. Risks of its use include an increase in arterial thrombosis. However, animal studies have not shown complications as seen in humans, in fact same of the studies show a better prognosis. In the military settings it is used as an off label intervention in complications related to disseminated intravascular coagulation related haemorrhage caused by penetrating trauma.Recombinant human factor VII while initially looking promising in intracerebral hemorrhage failed to show benefit following further study and this is no longer recommended. Interactions
Factor VII has been shown to interact with tissue factor and protein kinase C.

References
Further reading
External links
Official website
The MEROPS online database for peptidases and their inhibitors: S01.215
CHES - Comprehensive Health Education Services LLC - Factor VII treatment and awareness [1]